Software as a Medical Device for the Treatment of Patients With PTSD
A Multicenter, Randomized, Double-blind, Parallel-group Comparative Study to Assess Efficacy and Safety of Software as a Medical Device in Patients With Post-Traumatic Stress Disorder (PTSD)
1 other identifier
interventional
52
1 country
35
Brief Summary
To evaluate the efficacy and safety of Software as a Medical Device in patients with Post-Traumatic Stress Disorder (PTSD)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Sep 2024
Typical duration for phase_2
35 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 22, 2024
CompletedStudy Start
First participant enrolled
September 1, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 31, 2028
November 21, 2025
October 1, 2025
3.4 years
August 22, 2024
November 20, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Clinician-Administered PTSD Scale for DSM-5
The primary objective of this study is to assess the change from baseline of the Clinician Administered PTSD Scale (CAPS - 5) score. Scores range from 0 - 80, with higher scores indicating increased PTSD symptom severity.
baseline and after intervention (up to 21 weeks)
Study Arms (2)
The Software as a Medical Device1
EXPERIMENTALThe Software as a Medical Device2
OTHERInterventions
The subject will undergo treatment using the Software as a Medical Device
Eligibility Criteria
You may qualify if:
- Diagnosis of PTSD according to the DSM-5
- Subjects who are within 1 to 20 years since index trauma
You may not qualify if:
- Subjects diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, bipolar I disorder, autism spectrum disorder, or intellectual disability based on DSM-5.
- Subjects diagnosed with any mood disorder and anxiety disorder according to DSM-5 that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgement of the investigator
- Subjects who have completed two or more full courses of trauma-focused therapy in the past
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (35)
Yamanashi Prefectural Kita Hospital
Yamanashi, Hokkaido, Japan
Heart Care Clinic Omachi
Akita, Japan
Aburayama Hospital
Fukuoka, Japan
Ai Sakura Clinic
Fukuoka, Japan
Hatakeyama Clinic
Fukuoka, Japan
Hiro Mental Clinic
Fukuoka, Japan
Hirota Clinic
Fukuoka, Japan
Kurume University Hospital
Fukuoka, Japan
Medical corporation Shinseikai Kaku Mental Clinic
Fukuoka, Japan
Mental Clinic Sakurazaka
Fukuoka, Japan
Nishie Kokorono Clinic
Fukuoka, Japan
Uematsu Mental Clinic
Fukuoka, Japan
PTSD Care Matsumoto Mental Clinic
Gunma, Japan
Goryokai Hospital
Hokkaido, Japan
Sakamoto Misako Mental Clinic
Hyōgo, Japan
Takahashi Psychiatric Clinic
Hyōgo, Japan
Tsukuba Psychosomatics Clinic
Ibaraki, Japan
Musashikosugi J Kokorono Clinic
Kanagawa, Japan
Niki Hearty Hospital
Kumamoto, Japan
Arata Clinic
Nagasaki, Japan
Okayama Psychiatric Medical Center
Okayama, Japan
Barclay Imuro Mental Clinic
Okinawa, Japan
Medical Corporation Mikokorokai Shimizu Clinic
Osaka, Japan
Sho Midori Hospital
Saitama, Japan
Ai Mental Clinic
Tochigi, Japan
i Kokoro Clinic Nihonbashi
Tokyo, Japan
Iidabashi Mental Clinic
Tokyo, Japan
Ikebukuro Olive Mental Clinic
Tokyo, Japan
Kitaikebukuro Kokoro No Clinic
Tokyo, Japan
Maynds Tower Mental Clinic
Tokyo, Japan
Monzennakacho Mental Clinic
Tokyo, Japan
Nippon Medical School Hospital
Tokyo, Japan
Sakurazaka Clinic SophyAnce
Tokyo, Japan
Sangenjaya Nakamura Mental Clinic
Tokyo, Japan
Wakamatsucho Kokoro to Hifu Clinic
Tokyo, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 22, 2024
First Posted
September 19, 2024
Study Start
September 1, 2024
Primary Completion (Estimated)
January 31, 2028
Study Completion (Estimated)
January 31, 2028
Last Updated
November 21, 2025
Record last verified: 2025-10